Denali Therapeutics Inc. (DNLI:NASDAQ) closed at $18.74 on November 13, 2026, down 0.79% on the day. The stock trades 31.4% below its 52-week high of $27.30 and 22.2% above its 52-week low of $15.34. Over the past year, it gained 7.5%. Denali Therapeutics Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, DNLI closed higher on 119 days (47%). Its best day was January 22, 2026 (+12.53%) and its worst was July 14, 2026 (-14.46%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 2 times.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Find more stocks like DNLI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.